'Ecstasy' and the use of sleep medications in a general community sample: a 4-year follow-up
Aims: Animal models show that a single dose of MDMA (‘ecstasy’) can result in long-term disruption of sleep. We evaluated the relationship between ecstasy consumption and the use of sleep medications in humans after controlling for key factors. Design: The Personality and Total Health Through Life p...
| Main Authors: | , , |
|---|---|
| Format: | Journal Article |
| Published: |
Wiley-Blackwell Publishing Ltd.
2013
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.11937/17960 |
| _version_ | 1848749608204763136 |
|---|---|
| author | Tait, Robert George, A. Olesen, S. |
| author_facet | Tait, Robert George, A. Olesen, S. |
| author_sort | Tait, Robert |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Aims: Animal models show that a single dose of MDMA (‘ecstasy’) can result in long-term disruption of sleep. We evaluated the relationship between ecstasy consumption and the use of sleep medications in humans after controlling for key factors. Design: The Personality and Total Health Through Life project uses a longitudinal cohort with follow-up every four years. This study reports data from waves two and three. Setting: Participants were recruited from the electoral roll in the Australian Capital Territory and Queanbeyan, New South Wales, Australia. Participants: Participants were aged 20-24 years at wave one (1999-2000).Measures: The study collected self-reported data on ecstasy, meth/amphetamine, cannabis, alcohol, tobacco and use of sleeping medications (pharmaceutical or other substances). Depression was categorised with the Brief Patient Health Questionnaire (BPHQ). Other psychosocial measures included lifetime traumas. We used generalised estimating equations to model outcomes. Results: Ecstasy data were available from 2128 people at wave two and 1977 at wave three: sleeping medication use was reported by 227 (10.7%) respondents at wave two and 239 (12.1%) at wave three. Increased odds ratios (OR) for sleeping medication use was found for those with depression (OR=1.88, (95% confidence interval (CI) 1.39, 2.53), women (OR=1.44, 95% CI 1.13, 1.84), and increased by 19% for each lifetime trauma. Ecstasy use was not a significant predictor, but ≥monthly versus never meth/amphetamine use increased the odds (OR=3.03, 95% CI 1.30, 7.03). Conclusion: The use of ecstasy was not associated with the use of sleeping medications controlling for other risk factors. |
| first_indexed | 2025-11-14T07:23:38Z |
| format | Journal Article |
| id | curtin-20.500.11937-17960 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T07:23:38Z |
| publishDate | 2013 |
| publisher | Wiley-Blackwell Publishing Ltd. |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-179602019-02-19T05:34:54Z 'Ecstasy' and the use of sleep medications in a general community sample: a 4-year follow-up Tait, Robert George, A. Olesen, S. 3 cohort 4-Methylenedioxymethamphetamine (MDMA) ecstasy Longitudinal meth/amphetamine general community sample Aims: Animal models show that a single dose of MDMA (‘ecstasy’) can result in long-term disruption of sleep. We evaluated the relationship between ecstasy consumption and the use of sleep medications in humans after controlling for key factors. Design: The Personality and Total Health Through Life project uses a longitudinal cohort with follow-up every four years. This study reports data from waves two and three. Setting: Participants were recruited from the electoral roll in the Australian Capital Territory and Queanbeyan, New South Wales, Australia. Participants: Participants were aged 20-24 years at wave one (1999-2000).Measures: The study collected self-reported data on ecstasy, meth/amphetamine, cannabis, alcohol, tobacco and use of sleeping medications (pharmaceutical or other substances). Depression was categorised with the Brief Patient Health Questionnaire (BPHQ). Other psychosocial measures included lifetime traumas. We used generalised estimating equations to model outcomes. Results: Ecstasy data were available from 2128 people at wave two and 1977 at wave three: sleeping medication use was reported by 227 (10.7%) respondents at wave two and 239 (12.1%) at wave three. Increased odds ratios (OR) for sleeping medication use was found for those with depression (OR=1.88, (95% confidence interval (CI) 1.39, 2.53), women (OR=1.44, 95% CI 1.13, 1.84), and increased by 19% for each lifetime trauma. Ecstasy use was not a significant predictor, but ≥monthly versus never meth/amphetamine use increased the odds (OR=3.03, 95% CI 1.30, 7.03). Conclusion: The use of ecstasy was not associated with the use of sleeping medications controlling for other risk factors. 2013 Journal Article http://hdl.handle.net/20.500.11937/17960 10.1111/add.12200 Wiley-Blackwell Publishing Ltd. fulltext |
| spellingShingle | 3 cohort 4-Methylenedioxymethamphetamine (MDMA) ecstasy Longitudinal meth/amphetamine general community sample Tait, Robert George, A. Olesen, S. 'Ecstasy' and the use of sleep medications in a general community sample: a 4-year follow-up |
| title | 'Ecstasy' and the use of sleep medications in a general community sample: a 4-year follow-up |
| title_full | 'Ecstasy' and the use of sleep medications in a general community sample: a 4-year follow-up |
| title_fullStr | 'Ecstasy' and the use of sleep medications in a general community sample: a 4-year follow-up |
| title_full_unstemmed | 'Ecstasy' and the use of sleep medications in a general community sample: a 4-year follow-up |
| title_short | 'Ecstasy' and the use of sleep medications in a general community sample: a 4-year follow-up |
| title_sort | 'ecstasy' and the use of sleep medications in a general community sample: a 4-year follow-up |
| topic | 3 cohort 4-Methylenedioxymethamphetamine (MDMA) ecstasy Longitudinal meth/amphetamine general community sample |
| url | http://hdl.handle.net/20.500.11937/17960 |